Haifeng Cui is the Chief Scientific Officer and Head of R&D at Jemincare Group and sits on the executive council of Sino-American Pharmaceutical Professionals Association.
Currently Dr. Cui leads the R&D organization of Jemincare Group, advancing an extensive portfolio of innovative medicines into clinical stages. Before joining Jemincare, Dr. Cui was a senior director at J&J, where he performed search and evaluation for opportunities up to phase 2a to feed into the firm’s global pipeline and covered various sectors including infectious disease and vaccine, immunology, neuroscience, cardiovascular, and metabolic diseases in the APAC region. Prior to joining J&J, Dr. Cui began his drug discovery tenure at GSK in 2002 in the US, working across several therapeutic areas including cardiovascular, renal disease and infectious disease and leading multidisciplinary teams to deliver several compounds into clinic and follow-up to human PoC trial stages.
Dr. Cui received his PhD in organic chemistry from the University of Pennsylvania.
Chief Scientific Officer, Head of R&D, Jemincare Group;
SAPA-China Executive Council
Dr. Shaojing Hu is the founder, CEO and chairman of 3H Pharmaceuticals. Before founding 3H, Dr. Hu co-founded Jacobio Pharmaceuticals and served as its president and Head of R&D. In this capacity, Dr. Hu served as the key leader responsible for strategy planning, overseeing all in-house R&D efforts of and business development activities for strategy partnership. Prior to co-founding Jacobio, Dr. Hu served as the Chief Chemist and VP at Betta Pharmaceutics, where he was in charge of re-building the R&D team including all of early research functions and company oncology research activities and successfully led two program into clinical trials, as well as overseeing company IP department and early clinical development. Dr. Hu’s over-twenty-year pharmaceutical tenure covered diseases area such as oncology, immune-oncology, metabolic disease, CNS and anti-bacteria, and had extensive experiences in strategic planning and company management including R&D, fundraising, IPO, drug commercialization, as well as sales and marketing.
Dr. Hu received his Ph.D in Chemistry from Simon Fraser University in 1997 and worked for Prof. Allan Oehlschlager. He then moved to Yale University and worked for Prof. Craig Crews as postdoctoral fellow.
Founder, Chairman and CEO, 3H Pharmaceuticals
Darren is Chairman and CEO of Elpiscience Biopharmaceuticals. He was a Venture Partner of Lilly Asia Ventures (LAV) with whom he co-founded Elpiscience in 2017. Prior to that, Darren was Global Head and Vice President of Roche Partnering for Asia and Emerging Markets. In this role, Darren was responsible for driving the strategy and execution of business development activities encompassing over 100 countries.
A repeat entrepreneur himself, Darren spent a long career at the Procter & Gamble Company with increasing responsibilities in drug R&D and business development. He co-founded and served as CEO of PharmaLegacy Laboratories until 2012. Darren currently serves as a board director of Legend Biotech (NASDAQ: LEGN).
Darren got his M.D. from China Medical University, a PhD from University of Sheffield at UK, and a MBA from University of Chicago.
Co-founder, Chairman, and CEO of Elpiscience Biopharmaceuticals
Howard Liang is the President and Chief Financial Officer (CFO) at Tessera Therapeutics. Before joining Tessera, Dr. Liang was the CFO and Chief Strategy Officer at BeiGene for six years, where he helped lead the company’s growth from a research organization with fewer than 200 employees to a fully integrated global biotechnology company with more than 6,000 employees on five continents. Prior to BeiGene, Dr. Liang was the Managing Director and Head of Biotechnology Equity Research at Leerink Partners. Dr. Liang is also a member of the Hong Kong Stock Exchange Biotech Advisory Panel. Dr. Liang received his Ph.D. in Biochemistry and Molecular Biology and M.B.A. from the University of Chicago and his B.S. in Chemistry from Peking University.
President, Chief Financial Officer, Tessera Therapeutics
Tessera Therapeutics 总裁兼首席财务官
Jun Huang is an assistant professor of the Pritzker School of Molecular Engineering, Committee on Cancer Biology, Committee on Immunology, and the Graduate Program in Biophysical Sciences of the University of Chicago. His lab performs basic and translational research with the objective of developing effective vaccines and cell immunotherapies for the treatment of cancer, infection, and autoimmunity. He carries out basic immunological research, focusing on molecular mechanisms of T cell recognition and signaling at the single-molecule level. He performs systems immunology, studying the development, differentiation, and metabolism of T cells at the single-cell level. He engineers CAR-T cells, aiming at the treatment of cancer and autoimmunity. He develops new biomaterials, enabling the detection, profiling, and manipulation of T cells and other immune cells for diagnosis and treatment.
Assistant Professor of the Pritzker School of Molecular Engineering at the University of Chicago
As international scientific collaboration becomes the new paradigm in today’s world, this seminar explores the intricate yet dynamic relationship between the US and Chinese biopharmaceutical industry. Notable issues surrounding the sector—such as the global competitive landscape, key disruptions, regulatory & macro-environmental changes, and capital fundraising in venture-backed initiatives—will be addressed from multidimensional perspectives that aim to shed light on the future of a rapidly growing and increasingly pivotal industry.